Insights & Thought Pieces:
ASH 2025: Non-Malignant Hematology Abstracts Highlight
December 5, 2025 – API Senior Consultants James Perry and Thiviya Jeyakumar are on the ground in Orlando, Florida for the American Society of Hematology Annual Meeting. James assembled a guide to interesting abstracts covering a range of nonmalignant hematology indications. Read through for his take on presentations that may impact their respective fields.
5 Companies to Watch: AI in Drug Discovery
October 6, 2025 – As the Age of AI continues to reshape nearly every industry, its potential is only beginning to be realized in drug development. Our team highlighted five companies attempting to break the mold – utilizing AI to make drug development faster and more efficient. Flip through the full report to see which biotechs are leading the way, from identifying novel targets to advancing assets into clinical trials.
Spring 2025: FDA Approval Highlights
July 28, 2025 – Amidst all the attention-grabbing headlines, the important work of the FDA has continued. Here, the API team details 5 FDA approvals of interest during the first half of the year. From generics to vaccines to devices read on for a detailed look at approvals that may alter their respective markets!
EHA 2025: Non-Malignant Hematology Abstract Highlights
June 27, 2025 – While attending EHA2025, Senior Consultant James Perry had a front row seat to exciting new data in non-malignant hematology. Here are some of the most interesting presentations James saw at the conference in Milan!
Winter 2025: FDA Approval Highlights
February 13, 2025 – The FDA has been a frequent topic in recent news – but the organization’s important work has continued, approving new therapies for an array of indications. The Anchor Point team has rounded up some of the recent approvals we find particularly noteworthy. Take a look and let us know if you have any additional insights for these exciting new therapies.
ASH 2024: Non-Malignant Hematology Abstract Highlights
December 5, 2024 – The API team is back in San Diego for the hashtag ASH2024 meeting! While the team will be focused on oncology indications, Senior Consultant James Perry profiles some of the interesting data to be presented in non-malignant hematology. New and updated data in sickle cell disease, immune thrombocytopenia, and autoimmune indications caught his eye.
Q3 2024: Vaccine News Roundup
November 25, 2024 – With vaccine season in full swing in America, the conversation is heating up! From updates on potential political appointments to changes in CDC guidance, vaccines have been generating widespread discussion lately. But how has all the recent chatter affected the vaccine manufacturers? The Anchor Point team is taking a closer look at how the major RSV, COVID, Pneumonia, and Flu vaccine manufacturers performed in Q3 and what to expect in the months ahead.
Sickle Cell Disease: White Paper
Sep 30, 2024 – September is Sickle Cell Disease Awareness Month! As the month draws to a close, API’s James Perry reviews recent developments in the field and the future of SCD therapies. Despite striking advancements, including recent approvals of potentially curative treatments, current therapies are vastly underutilized. Improving access to care is a necessary first step before novel, more convenient treatments become available. Read through James’ white paper below!
ESMO 2024: Colorectal Cancer Abstract Highlights
September 13, 2024 – The API team is on the ground in Barcelona for this year’s ESMO meeting! We’re excited for the release of new data and long-awaited updates across multiple oncology indications. In particular, we’ll be following these interesting abstracts in colorectal cancer. Want to know more about the latest research and trends in colorectal cancer? Check out our recent white paper following the FDA’s approval of the first blood test screening for CRC.
Summer 2024: FDA Approval Highlights
August 26, 2024 – The API team has assembled five noteworthy approvals from the FDA this summer. Spanning a variety of indications, the approvals include new modalities and novel improvements to existing assets. We look forward to seeing how these assets are incorporated into their respective markets.
The Rise of Early Onset Colorectal Cancer
Aug. 12, 2024 – Recently, the FDA approved the first-ever blood test for colorectal cancer screening for adults of average cancer risk. Although there are still several limitations, this approval comes at a crucial time, as researchers grapple with the rising incidence of early-onset colorectal cancer (EOCRC). In this white paper, API’s Thiviya Jeyakumar summarizes the latest in EOCRC trends and CRC screening methods.